Stock Picks From The Pros
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had a turbulent couple of days of trading, but Echelon Wealth Partners … [Read more...] about Antibe Therapeutics is undervalued, Echelon analyst Loe says
Investment bankers Paradigm Capital launched coverage on Wednesday of drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News … [Read more...] about Will Antibe Therapeutics break out in 2020?
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has performed well both over the past year and during the current market … [Read more...] about Antibe Therapeutics is a “Top Pick” at Echelon Wealth
Canadian Life Sciences stocks have been on a roller coaster ride so far in 2019. The sector, which is comprised of drug and medical device … [Read more...] about Three Canadian Life Sciences stocks to watch for 2020
Echelon Wealth Partners analyst Douglas Loe is holding steady on his investment thesis for clinical stage drug developer Antibe Therapeutics (Antibe … [Read more...] about Biotech penny stock Antibe Therapeutics has a huge upside: Echelon
Echelon Wealth Partners analyst Douglas Loe is staying bullish on clinical stage drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, … [Read more...] about Antibe Therapeutics has loads of upside, says Echelon Wealth
In an update to clients Wednesday, Echelon Wealth Partners analyst Douglas Loe remains bullish on clinical stage drug developer Antibe Therapeutics … [Read more...] about Antibe Therapeutics has an upside of 352 per cent, Echelon Wealth says
In a research update on Monday, Echelon Wealth Partners analyst Douglas Loe reiterated his “Speculative Buy” rating and $1.40 target price for … [Read more...] about Buy Antibe Therapeutics for a 318 per cent return, says Echelon Wealth
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart TSXV:ATE) may keep trading sideways for a while yet but the drug developer’s ATB-346 … [Read more...] about Antibe Therapeutics has huge upside, Echelon Wealth says
In a coverage launch on Thursday, Echelon Wealth Partners analyst Douglas Loe says clinical stage drug developer Antibe Therapeutics (Antibe … [Read more...] about Antibe Therapeutics has a 192 per cent upside, Echelon Wealth says
